High intensity ultrasound (HIUS) has been increasingly investigated as a possible tool in the treatment of many different tumor entities, e.g. cancers of prostate, kidney, liver, pancreaticobiliary and other intrabdominal malignancies [
1‐
3]. While HIUS is still under clinical evaluation, previous studies indicate its potential to improve overall antitumoral activity regardless of chemotherapeutic applications [
4]. Despite encouraging first clinical results [
5], no studies have been conducted yet to assess HIUS’ possible application in the treatment of peritoneal metastases (PM). In all previous clinical applications, the HIUS beam was “focused” on a single spot in the body (High intensity focused ultrasound, HIFU). However, while PM usually covers a large surface, its depth is only minimal. This might be one reason as to why HIFU has not been considered for peritoneal applications. This study aims to modify the conventional HIFU to a “non-focused” HIUS approach and assess its potential in PM treatment. While HIUS is assumed to impact the peritoneum when used in the treatment of liver cancer, the validity of this assumption remains unclear [
6]. Considering that any interaction with the peritoneum may be used in a therapeutic capacity, and inaccessibility remains one of the main difficulties in PM treatment, it seems astonishing that HIUS has never been investigated as a potential tool in PM treatment. PM is a common manifestation of advanced gastrointestinal and gynecological cancers, and affected patients usually have a very poor prognosis with median survival rates of only a few months [
7]. Recent studies indicate that the combination of HIUS with intraperitoneal chemotherapy (IPC) could significantly increase drug penetration depths and therefore enhance the overall antitumoral effect, especially when applied with liposomal doxorubicin [
8,
9]. While this effect has mostly been attributed to the rupture of liposomal doxorubicin [
10], the results partially exceeded penetration levels observed in conventional chemotherapeutic solutions [
8]. At the same time, no structural damage to the peritoneum was detected. Still, some authors have suggested that HIUS might affect the peritoneal surface when accidently applied during hepatocellular carcinoma treatment (HCC) [
6]. To our knowledge, neither the application of HIUS and its potential, nor its possible side effects on the peritoneum have ever been systematically studied in the context of PM. In general surgery, HIUS is an established procedure predominantly used in the treatment of HCC [
11,
12]. In a previous study, HIUS was assumed to cause local heat on the peritoneum, which could possibly induce peritoneal tissue destruction [
6]. However, recent clinical evaluations indicate that HIUS might be safe for intraperitoneal use [
13]. Knowing the antitumoral properties demonstrated by HIUS in HCC, it seems reasonable to assume similar effects in PM. Thus, with respect to its low invasiveness and absence of radiation, HIUS may potentially play an important role in future PM treatment. To evaluate the structural effects of HIUS on the peritoneum, we studied a well-established ex-vivo model in which we investigated peritoneal samples following HIUS application using light, fluorescence and electron microscopy.